Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial

MLA

M. Zappimbulso, et al. “Antiviral Activity and Safety Profile of Silibinin in HCV Patients with Advanced Fibrosis after Liver Transplantation: A Randomized Clinical Trial.” Transplant International, vol. 27, May 2014, pp. 696–704. EBSCOhost, https://doi.org/10.1111/tri.12324.

APA

M. Zappimbulso, N.M. Castellaneta, Nadia Brambilla, Giampaolo Giacovelli, Alfredo Di Leo, A. Castellaneta, Massimo D’Amato, Lucio C. Rovati, Salvatore Fabio Rizzi, Maria Rendina, & R. Bringiotti. (2014). Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Transplant International, 27, 696–704. https://doi.org/10.1111/tri.12324

Chicago

M. Zappimbulso, N.M. Castellaneta, Nadia Brambilla, Giampaolo Giacovelli, Alfredo Di Leo, A. Castellaneta, Massimo D’Amato, et al. 2014. “Antiviral Activity and Safety Profile of Silibinin in HCV Patients with Advanced Fibrosis after Liver Transplantation: A Randomized Clinical Trial.” Transplant International 27 (May): 696–704. doi:10.1111/tri.12324.